Drugs / MV-ZIKA-RSP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04033068 | Aug 2019 → Jan 2020 | Zika virus infectious disease | Themis Bioscience GmbH | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MV-ZIKA-RSP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04033068 ↗ |
| Known as | ZIKA-RSP | “This is an observer-blinded, block-randomized, dose-finding, phase I trial, comparing different dose levels of MV-ZIKA-RSP to evaluate the safety, tolerability, and...” NCT04033068 ↗ |
| Modality | Vaccine | “a novel liquid vaccine formulation named MV-ZIKA-RSP” NCT04033068 ↗ |